Skip to main content

Table 11 Cumulative probability of efficacies and toxicities of different CCRT regimens in the treatment of LA-NSCLC

From: A network meta-analysis for efficacies and toxicities of different concurrent chemoradiotherapy regimens in the treatment of locally advanced non-small cell lung cancer

Treatment

SUCRA values (%)

ORR

1-year OS rate

2-year OS rate

3-year OS rate

Anemia

Leukopenia

Neutropenia

Thrombocytopenia

Febrile neutropenia

Nausea/vomiting

Esophagitis

Pneumonitis

A

32.0

72.5

79.7

89.4

44.3

55.2

76.3

58.2

49.4

59.1

51.0

49.0

B

64.1

78.4

68.6

49.1

39.3

NR

21.6

32.9

16.7

32.4

53.7

69.2

C

7.3

NR

NR

NR

NR

NR

NR

NR

NR

NR

56.2

56.3

D

37.2

70.4

79.7

95.1

26.7

40.7

45.0

44.2

12.0

50.1

50.1

45.6

E

33.2

45.3

33.0

51.4

42.5

NR

10.3

27.5

77.9

73.1

47.1

86.8

F

64.6

62.7

83.8

77.8

47.7

25.5

NR

47.9

NR

45.4

73.5

36.7

G

67.3

76.5

51.1

47.1

77.9

NR

65.8

81.3

NR

59.1

33.1

90.1

H

47.8

52.4

81.8

75.4

53.7

71.4

NR

48.2

99.8

26.1

75.2

54.8

I

48.8

49.7

48.7

41.8

48.3

17.9

NR

43.5

NR

40.1

55.2

26.9

J

NR

NR

NR

NR

NR

NR

NR

NR

NR

NR

NR

17.7

K

38.3

7.9

3.5

5.2

42.6

17.9

NR

NR

NR

29.8

36.9

23.0

L

70.8

11.2

27.9

28.4

NR

NR

NR

NR

NR

56.4

76.9

NR

M

19.8

85.9

68.2

66.3

46.6

48.4

NR

51.0

NR

77.2

16.9

69.8

N

53.3

62.3

56.2

43.5

55.6

NR

81.0

65.3

44.2

43.6

19.5

74.1

O

75.9

38.4

27.3

22.9

NR

82.8

NR

NR

NR

84.6

59.4

45.6

P

68.2

19.1

25.7

29.5

NR

NR

NR

NR

NR

NR

44.1

35.5

Q

73.2

NR

NR

NR

74.7

NR

NR

NR

NR

NR

43.2

26.8

R

48.1

17.3

14.8

27.3

NR

90.2

NR

NR

NR

23.2

58.2

42.4

  1. A, CCRT (cisplatin + etoposide); B, CCRT (carboplatin + paclitaxel); C, CCRT (pemetrexed + carboplatin); CCRT Concurrent chemoradiotherapy; D, CCRT (pemetrexed + cisplatin); E, CCRT (docetaxel + cisplatin); F, CCRT (S-1 + cisplatin); G, CCRT (mitomycin + vindesine + cisplatin); H, CCRT (cisplatin + vinorelbine); I, CCRT (cisplatin); J, CCRT(etoposide + cisplatin + amifostine); K, RT; L, CCRT (5-FU); LA-NSCLC Locally advanced non-small cell lung cancer; M, CCRT (paclitaxel + cisplatin); N, CCRT (irinotecan + carboplatin); NR Not report; O, CCRT (nedaplatin); ORR Objective response rate, OS Overall survival; P, CCRT (carboplatin + etoposide); Q, CCRT (paclitaxel); R, CCRT (carboplatin); SUCRA Surface under the cumulative ranking